Action Pharma Raises EUR 15 Million from Investors

Action Pharma A/S has announced that it has signed a financing agreement with new and existing investors, raising a total of EUR 15 million. Swiss/German Global Life Science Ventures and Scandinavian SLS Venture will as new investors invest a total of EUR 8 million, while the existing investors InnovationsKapital of Sweden, Sunstone Capital and Inventure Capital of Denmark will invest a total of EUR 7 million.

The raised capital allows Action Pharma to further develop its pipeline of drug candidates, currently comprising 7 projects of which two are in clinical development. The most advanced project is AP214 for the prevention of organ damage in connection with major surgery for life threatening cardiovascular diseases. A clinical Phase II trial in the US is expected to be initiated in the first half of 2008. The company's second clinical compound, AP1030, focused on the treatment of Type 2 diabetes, will complete an initial Phase I clinical study in Sweden in the first quarter of 2008.

For further information please contact:

Søren Nielsen,

CEO

Tel: +45 2323 4533

Email: sn@actionpharma.com

Or visit: www.actionpharma.com

Home > News & Events > News > Action Pharma Raises EUR 15 Million from Investors
Last updated: 2008-01-31

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

ACTION PHARMA A/S

ACTION PHARMA A/S

Action Pharma is a Danish biotech company founded in 2000 with focus on preclinical and clinical/regulatory development of pharmaceutical active derivates of melanocortin receptor agonists as novel pharmaceuticals. Action Pharma has an extensive in-house expertise within integrative pharmacology all...